Autoimmune Hepatitis (Adult)

1. Clinical Overview

Summary

Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease characterised by the triad of interface hepatitis on histology, hypergammaglobulinaemia (predominantly IgG elevation), and circulating autoantibodies. [1,2] The condition results from a breakdown of immunological tolerance to hepatocyte antigens, leading to T-cell mediated hepatocyte destruction. AIH demonstrates a striking female predominance with a sex ratio of approximately 4:1 and exhibits a bimodal age distribution with peaks during adolescence/young adulthood (10-30 years) and perimenopause (40-60 years). [1,3]

The International Autoimmune Hepatitis Group (IAIHG) classifies AIH into two principal subtypes based on serological profiles: Type 1 AIH (approximately 80% of cases) is defined by positivity for antinuclear antibodies (ANA) and/or anti-smooth muscle antibodies (SMA), while Type 2 AIH (approximately 20%) is characterised by anti-liver kidney microsomal type 1 (LKM-1) or anti-liver cytosol type 1 (LC-1) antibodies. [2,4] Type 2 AIH typically presents at a younger age, follows a more aggressive clinical course, and demonstrates higher relapse rates following treatment withdrawal.

The natural history of untreated AIH is progressive fibrosis culminating in cirrhosis, with historical cohort studies demonstrating 5-year mortality rates of 50% in patients with severe untreated disease. [5] However, AIH is highly responsive to immunosuppressive therapy, with standard induction using prednisolone combined with azathioprine achieving biochemical remission in 80-90% of patients. [1,6] This dramatic treatment response transforms the prognosis, with 10-year survival rates exceeding 90% in adequately treated patients. [5,7]

Early diagnosis and prompt initiation of immunosuppression are critical to prevent progression to cirrhosis and its complications. Notably, 25-30% of patients already have established cirrhosis at the time of initial diagnosis, emphasising the importance of considering AIH in the differential diagnosis of any unexplained chronic hepatitis. [1,8]

Key Facts

Clinical Pearls

The Chameleon Diagnosis: AIH can present acutely mimicking viral hepatitis, insidiously as chronic fatigue, or fulminantly with acute liver failure. The key is to include AIH in the differential for ANY unexplained hepatitis and routinely check autoantibodies and IgG levels.

The 80-90% Response Paradox: AIH responds exceptionally well to immunosuppression—failure to achieve biochemical remission within 6-12 months should prompt reassessment of diagnosis (consider overlap syndrome, variant AIH, or alternative diagnoses), evaluation of treatment adherence, and assessment of drug dosing.

Seronegative AIH Exists: Up to 10-20% of patients with histologically typical AIH may be autoantibody-negative at presentation. Serial testing and consideration of less commonly tested antibodies (SLA/LP, pANCA) may help. [4,12]

The Relapse Reality: AIH is essentially a lifelong disease for most patients. Treatment withdrawal attempts result in relapse rates of 50-87%, with each relapse increasing fibrosis risk. Many hepatologists now advocate indefinite maintenance therapy. [10,11]

Type 2 Warning: Type 2 AIH (LKM-1 positive) presents in younger patients, runs a more aggressive course, and has higher relapse rates. These patients often require lifelong immunosuppression and may benefit from earlier consideration of second-line agents. [2,4]

Why This Matters Clinically

AIH represents one of the few chronic liver diseases with a dramatic and sustained response to medical therapy. The contrast between treated and untreated outcomes is stark: untreated severe AIH carries a 5-year mortality of approximately 50%, while treated patients achieve 10-year survival rates exceeding 90%. [5,7] This makes early recognition and treatment initiation critically important.

The disease has significant implications beyond the liver. AIH patients frequently have concurrent autoimmune conditions (25-50%), including autoimmune thyroiditis, rheumatoid arthritis, type 1 diabetes mellitus, and inflammatory bowel disease. [13] Recognition of these associations aids both diagnosis and holistic patient management.

Furthermore, AIH serves as a model for understanding hepatic autoimmunity and immunological tolerance. The mechanisms underlying AIH pathogenesis inform our understanding of drug-induced liver injury, viral hepatitis, and liver transplant rejection.

---

2. Epidemiology

Global Incidence and Prevalence

The epidemiology of AIH has been extensively studied in European and North American populations, with more limited data from other regions. Reported prevalence rates vary considerably by geographic region and study methodology. [9]

The notably high prevalence in Alaskan Native populations (42.9 per 100,000) suggests significant genetic and possibly environmental factors influencing disease susceptibility. [9] Studies indicate that AIH incidence may be increasing, though this likely reflects improved recognition and diagnosis rather than a true increase in disease occurrence. [14]

Demographics

Sex Distribution

AIH demonstrates a pronounced female predominance across all populations studied. The female-to-male ratio is approximately 3.6-4:1 for Type 1 AIH and even higher (9:1) for Type 2 AIH. [1,3] This sexual dimorphism is believed to reflect the influence of sex hormones on immune regulation, with oestrogens generally promoting humoral immunity and autoimmune responses.

Age Distribution

The age distribution of AIH is characteristically bimodal:

Importantly, AIH can present at any age, including in elderly patients (>65 years). Elderly-onset AIH may present atypically and is often initially misdiagnosed as drug-induced liver injury. [16]

Ethnic Variation

While AIH affects all ethnic groups, clinical presentation and outcomes demonstrate ethnic variation:

Risk Factors and Associations

Genetic Susceptibility

AIH demonstrates strong genetic associations, particularly with human leukocyte antigen (HLA) alleles:

Non-HLA genetic associations include polymorphisms in:

• CTLA-4 (cytotoxic T-lymphocyte antigen 4)
• TNFA (tumour necrosis factor alpha)
• FAS (CD95/APO-1)
• Vitamin D receptor
• SH2B3 [18]

Associated Autoimmune Conditions

AIH frequently coexists with other autoimmune disorders, reflecting shared genetic susceptibility:

Environmental Triggers

Several environmental factors have been implicated in AIH initiation:

---

3. Pathophysiology

Immunological Mechanisms

AIH results from a complex interplay between genetic susceptibility, environmental triggers, and immune dysregulation leading to loss of tolerance against hepatocyte self-antigens. [2,18]

Stage 1: Initiation—Loss of Immune Tolerance

The initiating event in AIH involves breakdown of immunological tolerance to hepatocyte-specific antigens. Normal hepatic tolerance mechanisms include:

Hepatic Tolerance Mechanisms (Normal State)

In AIH, these tolerance mechanisms fail due to:

1. Genetic defects in immune regulation (HLA associations, CTLA-4 polymorphisms)
2. Numerical or functional Treg deficiency observed in AIH patients [18]
3. Environmental triggers initiating autoimmune cascades through molecular mimicry
4. Cytokine imbalance favouring pro-inflammatory (Th1/Th17) over regulatory responses

Stage 2: Autoantibody Production and Significance

Autoantibodies are serological hallmarks of AIH, though they serve primarily as diagnostic markers rather than direct mediators of hepatocyte injury. [2,4]

Type 1 AIH Autoantibodies

Type 2 AIH Autoantibodies

Anti-SLA/LP: The Prognostic Marker

Anti-soluble liver antigen/liver-pancreas antibodies deserve special mention. Present in 10-30% of AIH patients, anti-SLA/LP is:

• Highly specific for AIH (>95% specificity)
• Associated with more severe disease course
• Predictive of relapse after treatment withdrawal
• May identify seronegative AIH cases [4,12]

The target antigen for anti-SLA/LP is a cytoplasmic protein involved in selenocysteine biosynthesis (Sep tRNA:Sec tRNA synthase).

Stage 3: T-Cell Mediated Hepatocyte Destruction

The effector phase of AIH is predominantly T-cell mediated, distinguishing it from antibody-mediated organ damage seen in other autoimmune conditions. [2,18]

Cellular Immunopathology

Molecular Pathogenesis Pathway

GENETIC SUSCEPTIBILITY (HLA-DR3/DR4)
              ↓
ENVIRONMENTAL TRIGGER (virus, drug, xenobiotic)
              ↓
HEPATOCYTE ANTIGEN RELEASE/EXPOSURE
              ↓
ANTIGEN PRESENTATION BY HLA CLASS II
(on hepatocytes aberrantly expressing HLA-II,
 or professional APCs in portal tracts)
              ↓
CD4+ T CELL ACTIVATION
              ↓
┌─────────────────┬─────────────────┐
↓                 ↓                 ↓
Th1 RESPONSE    Th17 RESPONSE    B CELL HELP
IFN-γ, TNF-α    IL-17, IL-22     Autoantibody
                                  production
↓                 ↓                 
CD8+ CTL         Neutrophil       (Markers, not
ACTIVATION       recruitment       primary effectors)
↓                 ↓
HEPATOCYTE APOPTOSIS/NECROSIS
(Perforin/Granzyme B; Fas/FasL; TNF-α)
              ↓
INTERFACE HEPATITIS
              ↓
CHRONIC INFLAMMATION → FIBROSIS → CIRRHOSIS

Cytokine Profile in AIH

Stage 4: Histological Consequences—Interface Hepatitis

The characteristic histological lesion of AIH is interface hepatitis, reflecting the immunological attack at the portal-parenchymal interface. [1,2]

Histopathology

Interface Hepatitis (Piecemeal Necrosis)

Interface hepatitis is the defining histological feature of AIH, characterised by:

Microscopic Features

Advanced/Severe Disease Features

Plasma Cell Prominence

The presence of plasma cells within the portal infiltrate is a characteristic feature of AIH, though not pathognomonic. Plasma cells are typically:

• Present throughout the portal infiltrate
• May cluster at the interface
• Produce immunoglobulins locally (hence elevated serum IgG)
• Distinguished from lymphocytes by their eccentric nucleus and basophilic cytoplasm

Differential Histological Features

Classification Systems

AIH Type 1 vs Type 2

Overlap Syndromes

Overlap syndromes occur when features of AIH coexist with features of other autoimmune liver diseases:

AIH-PBC Overlap

AIH-PSC Overlap

Drug-Induced AIH-Like Syndrome

Certain medications can induce a syndrome indistinguishable from idiopathic AIH: [19]

---

4. Clinical Presentation

Spectrum of Presentation

AIH demonstrates a highly variable clinical presentation, ranging from asymptomatic to fulminant liver failure. This variability often leads to delayed diagnosis. [1,2]

Modes of Presentation

Symptoms

Common Symptoms

Symptoms Suggesting Severe/Acute Disease

Signs

Physical Examination Findings

Signs of Associated Autoimmune Conditions

Red Flags and Emergency Features

[!CAUTION] Red Flags Requiring Urgent Specialist Assessment

• Jaundice with INR >1.5 — Synthetic dysfunction; potential acute liver failure
• Hepatic encephalopathy — Any grade; indicates severe hepatic dysfunction
• MELD score ≥12 — Associated with mortality without transplant in acute severe AIH
• Rapidly rising bilirubin — >50 μmol/L increase over days
• No improvement after 7-14 days of high-dose corticosteroids — Consider transplant listing
• Massive transaminase elevation — AST/ALT >1000 U/L with coagulopathy

Presentations Requiring Special Consideration

Acute Severe AIH

Acute severe AIH presents with features of acute hepatitis and may progress to acute liver failure: [20]

AIH Presenting as Cirrhosis

25-30% of AIH patients present with established cirrhosis: [1,8]

• May have minimal current inflammation (biochemically and histologically "burnt out")
• Still warrant treatment if active inflammation present
• Management includes cirrhosis surveillance (varices, HCC screening)
• Transplant assessment if decompensated

---

5. Clinical Examination

Structured Examination Approach

General Inspection

Hand Examination

Abdominal Examination

Chronic Liver Disease Stigmata

---

6. Investigations

Diagnostic Approach

The diagnosis of AIH requires integration of clinical, biochemical, serological, and histological features. The International Autoimmune Hepatitis Group (IAIHG) has developed diagnostic scoring systems to standardise diagnosis. [1,2]

Laboratory Investigations

Liver Function Tests

Biochemical Patterns

Immunological Tests

Immunoglobulins

Autoantibody Panel

Autoantibody Interpretation Caveats

• Up to 10-20% of histologically typical AIH is seronegative at presentation
• Low-titre positivity (1:40) may occur in healthy individuals and other liver diseases
• Serial testing may reveal positivity in initially seronegative cases
• Anti-SLA/LP testing should be considered in seronegative cases [4,12]

Exclusion of Other Liver Diseases

Imaging

Liver Biopsy

Liver biopsy remains important for diagnosis and staging, though not absolutely required in all cases.

Indications for Liver Biopsy

When Biopsy May Be Deferred

• Coagulopathy (INR >1.5) or thrombocytopenia (less than 50,000)
• Classic clinical and serological features with clear diagnosis
• Acute severe presentation requiring immediate treatment
• Patient refusal (diagnosis may be presumptive)

Histological Scoring

Diagnostic Criteria

Simplified IAIHG Diagnostic Criteria (2008)

The simplified criteria provide a practical diagnostic tool: [2]

Interpretation

Sensitivity and Specificity

The simplified criteria have been validated with sensitivity of 88% and specificity of 97% for distinguishing AIH from other chronic liver diseases. [2]

Original (Revised) IAIHG Criteria (1999)

The original comprehensive scoring system provides more granular assessment and is useful in atypical cases:

Interpretation (Pre-Treatment)

---

7. Management

Treatment Principles

The goals of AIH treatment are: [1,6]

1. Induce remission — Normalise transaminases and IgG
2. Maintain remission — Prevent flares and disease progression
3. Prevent cirrhosis — Halt fibrosis progression
4. Minimise treatment toxicity — Steroid-sparing strategies
5. Optimise quality of life — Manage symptoms and side effects

Management Algorithm

                      DIAGNOSED AIH
                           ↓
          ┌────────────────┴────────────────┐
          ↓                                 ↓
    ACUTE SEVERE                      STANDARD PRESENTATION
    (Jaundice + INR >1.5)             (Most patients)
          ↓                                 ↓
    High-dose steroids              INDUCTION THERAPY
    ± Early transplant              Prednisolone 30-40mg OD
       assessment                   + Azathioprine 50mg OD
          ↓                         (after checking TPMT)
    Response in 7-14 days?                  ↓
          ↓                         MONITOR RESPONSE
    Yes → Standard taper            (LFTs, IgG every 2-4 weeks)
    No → Transplant listing                 ↓
                                    RESPONSE (4-8 weeks)?
                                           ↓
                         ┌─────────────────┴─────────────────┐
                         ↓                                   ↓
                    YES: Remission                     NO: Non-response
                         ↓                                   ↓
                    MAINTENANCE                        Review diagnosis
                    Taper prednisolone                 Check adherence
                    Increase azathioprine              Consider overlap
                    (1-2 mg/kg)                        Increase doses
                         ↓                                   ↓
                    Target: Steroid-free               SECOND-LINE THERAPY
                    remission on azathioprine          (see below)
                         ↓
          ┌─────────────────────────────────┐
          ↓                                 ↓
    SUSTAINED REMISSION              RELAPSE ON TAPER
    (≥2 years, normal LFTs/IgG)      OR WITHDRAWAL
          ↓                                 ↓
    Consider treatment               Re-induce with steroids
    withdrawal trial                 Return to maintenance
    (50-87% relapse risk)            Consider lifelong Rx

Indications for Treatment

When Treatment May Be Deferred

• Minimal histological activity without fibrosis
• Asymptomatic with mild biochemical abnormality
• Significant comorbidities making immunosuppression high-risk
• Patient preference with informed discussion

Induction Therapy

Standard Induction Regimen

Combination Therapy (Preferred)

Monotherapy Alternative

Prednisolone Tapering Protocol

Azathioprine: Practical Considerations

Pre-Treatment Assessment

TPMT and Dosing

Monitoring During Azathioprine Therapy

Maintenance Therapy

Goals of Maintenance

Maintenance Regimens

Treatment Targets and Monitoring

Treatment Withdrawal

Considerations for Treatment Cessation

Treatment withdrawal may be considered after sustained remission, but carries significant relapse risk: [10,11]

Criteria for Considering Withdrawal

Relapse After Withdrawal

Withdrawal Protocol (If Attempted)

Current Consensus

Many hepatologists now advocate indefinite maintenance therapy for most AIH patients given the high relapse rates and consequences of repeated relapses. [1,10,11]

Refractory and Difficult-to-Treat Disease

Non-Response to Standard Therapy

Non-response is defined as failure to achieve biochemical remission despite adequate treatment. Consider:

Second-Line Therapy

Third-Line/Emerging Therapies

Special Situations

Acute Severe AIH

AIH in Pregnancy

AIH with Cirrhosis

AIH-Overlap Syndromes

AIH-PBC Overlap

AIH-PSC Overlap

---

8. Complications

Disease-Related Complications

Progression to Cirrhosis

Portal Hypertension

Hepatocellular Carcinoma

Acute Liver Failure

Treatment-Related Complications

Corticosteroid Side Effects

Azathioprine Side Effects

Complications of Relapse

---

9. Prognosis and Outcomes

Natural History

Untreated AIH

Treated AIH

Prognostic Factors

Survival Data

Liver Transplantation

---

10. Evidence and Guidelines

Key Clinical Practice Guidelines

Landmark Studies and Evidence Base

Diagnostic Criteria Development

Treatment Evidence

Prognosis and Outcomes

Difficult-to-Treat Disease

Evidence Strength Summary

---

11. Patient/Layperson Explanation

What is Autoimmune Hepatitis?

Autoimmune hepatitis (AIH) is a condition where your body's immune system, which normally fights infections, mistakenly attacks your own liver cells. This causes inflammation (swelling) in the liver, which over time can lead to scarring called cirrhosis.

AIH is more common in women than men and can occur at any age. It is not caused by alcohol, viruses, or anything you have done. It is part of a group of conditions called autoimmune diseases.

Why Does It Happen?

The exact cause is unknown, but it involves:

• Genetics: It can run in families and is linked to certain genes
• Immune system malfunction: Your immune cells attack liver cells as if they were foreign
• Triggers: Sometimes infections or medications may trigger the condition

How Is It Diagnosed?

Doctors diagnose AIH using:

1. Blood tests: Looking for specific antibodies (proteins made by the immune system) and raised immunoglobulin levels
2. Liver tests: Checking liver enzyme levels
3. Liver biopsy: A small sample of liver tissue examined under a microscope (not always necessary)

How Is It Treated?

AIH is treated with medications that calm down the immune system:

Treatment usually works very well—about 80-90% of people respond and can live normal, healthy lives with ongoing medication.

What Should I Expect?

• Initial treatment: Higher doses of steroids, which are gradually reduced
• Long-term: Most people need to take medication for many years, often lifelong
• Monitoring: Regular blood tests to check liver function and medication effects
• If treatment is stopped: There is a 50-80% chance the disease will come back (relapse)

Lifestyle Advice

When to Seek Help Urgently

Contact your doctor or go to hospital if you experience:

• Yellowing of eyes or skin (jaundice)
• Severe tiredness or confusion
• Dark urine or pale stools
• Easy bruising or bleeding
• Swollen abdomen

Prognosis

With proper treatment:

• 90% or more of people are alive and well after 10 years
• The liver can recover significantly if treatment is started early
• Many people lead completely normal lives

Without treatment, the disease can be serious and life-threatening. This is why it is so important to take your medication as prescribed and attend all your appointments.

---

12. References

Primary Guidelines

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971-1004. doi:10.1016/j.jhep.2015.06.030. PMID: 26341719

Diagnostic Criteria

2. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169-176. doi:10.1002/hep.22322. PMID: 18537184

Epidemiology

3. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. J Hepatol. 2014;60(3):612-617. doi:10.1016/j.jhep.2013.10.020. PMID: 24326218

Autoantibodies

4. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017. doi:10.1038/nrdp.2018.17. PMID: 29644994

Natural History and Prognosis

5. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011;55(1):171-182. doi:10.1016/j.jhep.2010.12.012. PMID: 21167232

Treatment

6. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213. doi:10.1002/hep.23584. PMID: 20513004

7. Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45(4):457-467. doi:10.3109/00365520903555861. PMID: 20100117

Cirrhosis at Presentation

8. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53-62. doi:10.1002/hep.20732. PMID: 15954109

Epidemiology (International)

9. Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382(9902):1433-1444. doi:10.1016/S0140-6736(12)62163-1. PMID: 23768844

Relapse and Withdrawal

10. van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141-147. doi:10.1016/j.jhep.2012.09.009. PMID: 22989569

11. Hartl J, Ehlken H, Weiler-Normann C, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015;62(3):642-646. doi:10.1016/j.jhep.2014.10.018. PMID: 25457206

Anti-SLA/LP Antibodies

12. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51(2):259-264. doi:10.1136/gut.51.2.259. PMID: 12117891

Associated Autoimmune Diseases

13. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44(3):208-213. doi:10.1097/MCG.0b013e3181c74e0d. PMID: 20087196

Danish Epidemiology

14. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. J Hepatol. 2014;60(3):612-617. doi:10.1016/j.jhep.2013.10.020. PMID: 24326218

Japanese Epidemiology

15. Takahashi A, Arinaga-Hino T, Ohira H, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol. 2017;52(5):631-640. doi:10.1007/s00535-016-1267-0. PMID: 27714505

Elderly-Onset AIH

16. Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45(4):575-583. doi:10.1016/j.jhep.2006.04.007. PMID: 16899323

Ethnic Variation

17. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46(6):1828-1835. doi:10.1002/hep.21884. PMID: 17705180

Genetics and Immunopathogenesis

18. Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25(6):653-664. doi:10.1016/j.bpg.2011.09.009. PMID: 22117632

Drug-Induced AIH

19. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040-2048. doi:10.1002/hep.23588. PMID: 20512992

Acute Severe AIH

20. Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61(4):876-882. doi:10.1016/j.jhep.2014.05.021. PMID: 24842308

---

Last Reviewed: 2025-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to current guidelines for patient management.